Global Pull Incentives for Better Antibacterials: The UK Leads the Way

por Outterson, Kevin, Rex, John H.
Publicado 2023

Anti-infectives: new trends, new approaches

por Rex, John H., Hayden, Frederick G.
Publicado 2007

The Value of the Information That Can Be Generated: Optimizing Study Design to Enable the Study of Treatments Addressing an Unmet Need for Rare Pathogens

por Dane, Aaron, Rex, John H, Newell, Paul, Stallard, Nigel
Publicado 2022

The evolution of the regulatory framework for antibacterial agents

por Rex, John H, Goldberger, Mark, Eisenstein, Barry I, Harney, Carrie
Publicado 2014

Designing development programs for non-traditional antibacterial agents

por Rex, John H., Fernandez Lynch, Holly, Cohen, I. Glenn, Darrow, Jonathan J., Outterson, Kevin
Publicado 2019

Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial Networks

por McDonnell, Anthony, Rex, John H., Goossens, Herman, Bonten, Marc, Fowler, Vance G., Dane, Aaron
Publicado 2016

594. An Open-Label Study in Healthy Volunteers to Determine the Absolute Bioavailability of, the Effect of Food and Dosing by Nasogastric Tube upon the Pharmacokinetics of a Single...

por Cornelissen, Karen, Newell, Paul A, Rex, John H, Galbraith, Hal, Israel, Samuel, Bush, James, ChB, M B
Publicado 2022

870. Olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: Comparison of interim results from a Phase 2B open-label study with o...

por Maertens, Johan A, Verweij, Paul E, Lanuza, Evan F, Harvey, Emma L, Dane, Aaron, Zinzi, Daniela, Rex, John H, Chen, Sharon C
Publicado 2022

Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance...

por Rex, John H, Talbot, George H, Goldberger, Mark J, Eisenstein, Barry I, Echols, Roger M, Tomayko, John F, Dudley, Michael N, Dane, Aaron
Publicado 2017

Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease

por Hope, William W., McEntee, Laura, Livermore, Joanne, Whalley, Sarah, Johnson, Adam, Farrington, Nicola, Kolamunnage-Dona, Ruwanthi, Schwartz, Julie, Kennedy, Anthony, Law, Derek, Birch, Michael, Rex, John H.
Publicado 2017

Developmental roadmap for antimicrobial susceptibility testing systems

por van Belkum, Alex, Bachmann, Till T., Lüdke, Gerd, Lisby, Jan Gorm, Kahlmeter, Gunnar, Mohess, Allan, Becker, Karsten, Hays, John P., Woodford, Neil, Mitsakakis, Konstantinos, Moran-Gilad, Jacob, Vila, Jordi, Peter, Harald, Rex, John H., Dunne, Wm. Michael
Publicado 2018

The successful uptake and sustainability of rapid infectious disease and antimicrobial resistance point-of-care testing requires a complex ‘mix-and-match’ implementation package...

por Hays, John P., Mitsakakis, Konstantinos, Luz, Saturnino, van Belkum, Alex, Becker, Karsten, van den Bruel, Ann, Harbarth, Stephan, Rex, John H., Simonsen, Gunnar Skov, Werner, Guido, Di Gregori, Valentina, Lüdke, Gerd, van Staa, Tjeerd, Moran-Gilad, Jacob, Bachmann, Till T.
Publicado 2019

Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed

por Butler, Mark S., Gigante, Valeria, Sati, Hatim, Paulin, Sarah, Al-Sulaiman, Laila, Rex, John H., Fernandes, Prabhavathi, Arias, Cesar A., Paul, Mical, Thwaites, Guy E., Czaplewski, Lloyd, Alm, Richard A., Lienhardt, Christian, Spigelman, Melvin, Silver, Lynn L., Ohmagari, Norio, Kozlov, Roman, Harbarth, Stephan, Beyer, Peter
Publicado 2022

When to change treatment of acute invasive aspergillosis: an expert viewpoint

por Slavin, Monica A, Chen, Yee-Chun, Cordonnier, Catherine, Cornely, Oliver A, Cuenca-Estrella, Manuel, Donnelly, J Peter, Groll, Andreas H, Lortholary, Olivier, Marty, Francisco M, Nucci, Marcio, Rex, John H, Rijnders, Bart J A, Thompson, George R, Verweij, Paul E, White, P Lewis, Hargreaves, Ruth, Harvey, Emma, Maertens, Johan A
Publicado 2021